Objectives: Primary 1) To evaluate the effectiveness of chlorhexidine bath in eradicating MRSA carriage.
Review question/objective
Objectives: Primary 1) To evaluate the effectiveness of chlorhexidine bath in eradicating MRSA carriage.
2) To evaluate the efficacy of chlorhexidine bath on MRSA incidence rate in the adult inpatient wards.
3) To evaluate the effectiveness of chlorhexidine bathing with or without topical decolonization therapy in reducing risk of MRSA infection among MRSA colonized inpatients.
Secondary:
1) To evaluate the development of MRSA infection and tolerance to chlorhexidine bath with or without topical decolonization therapy.
2) To assess the effectiveness of chlorhexidine bath on the rates of Blood Stream Infections (BSI).
Review Questions: 1) Can chlorhexidine bath reduce the acquisition rate of MRSA during their hospitalisation?
2) Is the use of chlorhexidine more effective in preventing incidence of MRSA than soap and water?
3) Is the combination of chlorhexidine bath and decolonization therapy more effective in the eradicating MRSA than chlorhexidine bath alone? 4) Can Chlorhexidine bath alone decrease blood stream infection? 3 
Background
Methicillin Resistant Staphylococcus Aureus (MRSA) was first described as a nosocomial pathogen in Europe in 1961. Nosocomial pathogen is defined as an agent of disease acquired in the hospital. 12 It is equivalent to Singapore's largest hospitals; each identifying on average of 2 to 3 MRSA bacteraemia per week. 13 Nosocomial infection is defined as infections identified in patients after 48 -72 hours of hospitalisation or 48 -72 hours after discharge from hospital in the absence of evidence of active or incubating infection on admission. 15 It is often termed as "hospital onset" and is defined using only information related to the timing of specimen collection in relation to hospital admissions. Specifically , it is recommended that hospital onset MRSA infection be considered if the organism is isolated after the 3rd calendar day of hospitalisation, with day 1 being the day of admission ( the admission day is the date of inpatient overnight stay not outpatient or/and emergency visits). 15 The prevalence rate of MRSA infection or colonisation is defined as the total number of patients with MRSA infection or colonisation in a specific population at a specific point of time MRSA (includes all old and new cases at point of per admission)
whereas, an incidence rate of MRSA infection or colonisation is the total number of patients with newly acquired MRSA infection or colonisation in a specific population during a specific period. 15 Thus, it is important to know which patients have a history of colonisation or infection in order to identify a prevalence or incidence rate. The number of admissions to hospital is used as the denominator for both prevalence and incidence rate. It is recommended to use a simple prevalence or incidence per 100 patients admitted to the hospital as it is easily understood. The number of patient days which is the population density (1000) is used as the denominator for calculation of prevalence density and incidence density; a better account for length of patient stay. 15 MRSA poses a major threat especially to the critically ill patients. 4 For the past 2-3 decades, the control of MRSA in hospitals in USA had been based on prompt identification of patients colonised with MRSA through active surveillance cultures (ASC) and reinforcement of contact precautions such as hand hygiene, as well as barrier precautions to decrease horizontal transmission between patients. [1] [2] [3] [4] [5] Unrecognised MRSA carriers, who are not placed under isolation precautions on admission is another contributing factor to the poor efficacy of infection control practices. 1, 3 Meanwhile, hand hygiene has been considered by many experts as the primary action to decrease healthcare associated infection and cross transmission of anti-microbial-resistant pathogens. 4 However, compliance to this simple, fast and effective procedure among health care workers remains low. 4 Therefore, additional strategies such as improving the stewardship of antibiotics, cohorting patients in dedicated unit, leadership support in training as well as designated staff to care only for MRSA patients are several other methods adopted to manage the rising hospital acquired MRSA. 4 There are more than 40
clinical trials examining the outcomes and or efficacy of chlorhexidine for a variety of conditions including Surgical Site Infections (SSIs), MRSA,
Vancomycin Resistant Enterococci (VRE) colonisation and nosocomial bacteremia. 6 Chlorhexidine is described as cationic bisbigunide that reverses the surface charge of bacterial cell, resulting in leakage of cytoplasmic contents and cell death. 2, 6 It reduces skin organism and inhibits their rebound growth and has been demonstrated to be more effective in decreasing catheter-associated Blood Stream Infection (BSIs) when compared to other skin disinfectant products like povidone and iodine. 3 Chlorhexidine based products are also said to decrease the density of skin colonisation with pathogens like MRSA and VRE, therefore, lowering the risk for horizontal transmission between patients and healthcare workers. 3 Chlorhexidine gluconate (CHG), meanwhile, in the form of 2% 5 or 4% solution, 2,5,7 as well as wipes or 2% CHGimpregnated clothes 8-9, had been shown to reduce BSI because of it's broad spectrum anti-microbial activity, durability and low toxicity. showed a positive reduction of MRSA infection where nasal mupirocin and daily chlorhexidine bath were used. 1 Another randomized clinical trial was conducted using oral chlorhexidine rinse and nasal mupirocin rinse, was compared with another group using the same treatment but included a Chlorhexidine body wash. The latter treatment showed a reduction of skin colonisation. 7 Despite these facts, the development of mupirocin resistance is still a major concern. Contamination with MRSA remains an ever increasing problem for the hospital. 
Types of intervention(s)/phenomena of interest
The use of chlorhexidine shower/bath/wipes/wash with or without combination of other pharmacological therapies such as antibiotics, topical decolonisation therapy for MRSA. The various administration methods, duration and frequency will be included in the review.
Types of Comparator
The comparator group includes no chlorhexidine shower (usual care with soap and water), with or without antibiotics or topical decolonisation therapy.
Types of outcomes
The outcomes of interest include: 2) Comparative Benefits of combination therapy with chlorhexidine shower with decolonisation therapy vs. chlorhexidine shower only.
3) Tolerance to chlorhexidine shower with or without decolonisation therapy.
4) Blood stream infection (with or without MRSA)

Types of studies
All Randomised Control Trails (RCTs) and all quasi -experimental studies examining the effectiveness of chlorhexidine shower in the treatment of MRSA with or without other combination therapy will be considered.
Search strategy
A search strategy was developed to guide the systematic review. Mesh terms from Pubmed were used to determine the words used to search in MEDLINE and CINAHL. The first search from MEDLINE and CINAHL 
Assessment of methodological quality
Articles selected for retrieval will be appraised by 2 reviewers independently for methodology validity prior to inclusion in the review using the standardised appraising instruments from Joanna Briggs Institute Meta Analysis Statistics Assessment and Review instrument (JBI-MAStaRI) (Appendix II). Any disagreement arising between the 2 reviewers will be resolved through discussion with a third reviewer.
Data collection
Data will be extracted from the articles included in the review using the standardised data extraction tool from JBI-MAStARi (Appendix III).
Data synthesis
Quantitative data may be pooled in statistical meta-analysis using JBIMAStARI. All results will be subjected to double data entry. Odd ratios (for categoric data) and weighted mean difference (for continuous data)
and their 95% confidence interval will be calculated for analysis.
Heterogeneity will be assessed using the standard Chi Square. Where pooling of statistical data is not possible, the findings will be presented in the narrative form.
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